Core Viewpoint - Spectrum Pharmaceuticals, Inc. is facing a class action lawsuit alleging false or misleading statements regarding its clinical trial for the drug poziotinib, which is intended for lung cancer treatment [2]. Group 1: Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies [1]. Group 2: Legal Proceedings - The class action lawsuit pertains to the Pinnacle Study, a clinical trial involving the drug poziotinib [2]. - The Lead Plaintiff appointment process has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [3]. Group 3: Shareholder Information - Shareholders do not need to participate in the case to be eligible for recovery [3]. - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4].
Spectrum Pharmaceuticals, Inc. (SPPI) Investors: Contact Robbins LLP for Information About the Class Action Against Spectrum Pharmaceuticals, Inc.
GlobeNewswire News Roomยท2025-08-11 23:21